Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG002C0106 in Normal and Mild-to-Moderate Renal Impairment
NCT07445906Phase 1Active, not recruiting
- Sponsor
- Rigerna Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, single-arm trial of RG002C0106 in IgA nephropathy (IgAN), sponsored by Rigerna Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at 4 days, Time to Maximum Plasma Concentration at 4 days and 7 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
RG002C0106
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07445906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445906.